drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00211 | DB00561 | 1,290 | 1,048 | [
"DDInter1213",
"DDInter591"
] | Midodrine | Doxapram | An ethanolamine derivative that is an adrenergic alpha agonist. It is used as a vasoconstrictor agent in the treatment of hypotension. | A central respiratory stimulant with a brief duration of action. (From Martindale, The Extra Pharmocopoeia, 30th ed, p1225) | Moderate | 1 | [
[
[
1290,
24,
1048
]
],
[
[
1290,
21,
28963
],
[
28963,
60,
1048
]
],
[
[
1290,
24,
144
],
[
144,
63,
1048
]
],
[
[
1290,
24,
1466
],
[
14... | [
[
[
"Midodrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxapram"
]
],
[
[
"Midodrine",
"{u} (Compound) causes {v} (Side Effect)",
"Anxiety"
],
[
"Anxiety",
"{u} (Side Effect) is caused by {v... | Midodrine (Compound) causes Anxiety (Side Effect) and Anxiety (Side Effect) is caused by Doxapram (Compound)
Midodrine may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol and Olodaterol may cause a moderate interaction that could exacerbate diseases when taken with Doxapram
Midodr... |
DB00590 | DB00741 | 1,433 | 167 | [
"DDInter592",
"DDInter885"
] | Doxazosin | Hydrocortisone | Doxazosin is an alpha-1 antagonist used for the treatment of benign prostatic hypertrophy (BPH) symptoms and hypertension. Other members of this drug class include [Prazosin], [Terazosin], [Tamsulosin], and [Alfuzosin]. Because of its long-lasting effects, doxazosin can be administered once a day. It is marketed by Pfi... | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone wa... | Moderate | 1 | [
[
[
1433,
24,
167
]
],
[
[
1433,
24,
1220
],
[
1220,
40,
167
]
],
[
[
1433,
24,
870
],
[
870,
1,
167
]
],
[
[
1433,
63,
251
],
[
251,
... | [
[
[
"Doxazosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
]
],
[
[
"Doxazosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
... | Doxazosin may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) resembles Hydrocortisone (Compound)
Doxazosin may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Hydr... |
DB08881 | DB12364 | 868 | 1,421 | [
"DDInter1925",
"DDInter200"
] | Vemurafenib | Betrixaban | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Betrixaban is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa . It was selected among all lead compounds due to its low hERG channel affinity while sustaining its factor Xa inhibition capacity . Betrixaban, now developed by Portola Pharmaceuticals ... | Major | 2 | [
[
[
868,
25,
1421
]
],
[
[
868,
63,
1091
],
[
1091,
24,
1421
]
],
[
[
868,
24,
1017
],
[
1017,
24,
1421
]
],
[
[
868,
64,
759
],
[
759,
... | [
[
[
"Vemurafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
]
],
[
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amprenavir"
],
[
"Amprenav... | Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Amprenavir and Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban
Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorl... |
DB00748 | DB01069 | 662 | 401 | [
"DDInter297",
"DDInter1533"
] | Carbinoxamine | Promethazine | Carbinoxamine is a first generation antihistamine that competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. The product label for carbinoxamine as an over the... | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Moderate | 1 | [
[
[
662,
24,
401
]
],
[
[
662,
24,
146
],
[
146,
24,
401
]
],
[
[
662,
1,
11275
],
[
11275,
40,
401
]
],
[
[
662,
24,
1264
],
[
1264,
... | [
[
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propiomazine"
]... | Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Propiomazine and Propiomazine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Carbinoxamine (Compound) resembles Chlorprothixene (Compound) and Chlorprothixene (Compound) resembles ... |
DB00014 | DB00978 | 521 | 739 | [
"DDInter839",
"DDInter1084"
] | Goserelin | Lomefloxacin | Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medi... | Lomefloxacin is a fluoroquinolone antibiotic, used to treat bacterial infections including bronchitis and urinary tract infections (UTIs). Additionally, it has been employed for the prophylaxis of UTIs prior to surgery as well. | Moderate | 1 | [
[
[
521,
24,
739
]
],
[
[
521,
25,
945
],
[
945,
40,
739
]
],
[
[
521,
24,
872
],
[
872,
40,
739
]
],
[
[
521,
25,
1176
],
[
1176,
1... | [
[
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomefloxacin"
]
],
[
[
"Goserelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sparfloxacin"
],
[
"Sparflox... | Goserelin may lead to a major life threatening interaction when taken with Sparfloxacin and Sparfloxacin (Compound) resembles Lomefloxacin (Compound)
Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Gemifloxacin and Gemifloxacin (Compound) resembles Lomefloxacin (Compound)
Goser... |
DB01128 | DB04844 | 918 | 843 | [
"DDInter204",
"DDInter1778"
] | Bicalutamide | Tetrabenazine | Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor. | A drug formerly used as an antipsychotic but now used primarily in the symptomatic treatment of various hyperkinetic disorders. It is a monoamine depletor and used as symptomatic treatment of chorea associated with Huntington's disease. FDA approved on August 15, 2008. | Moderate | 1 | [
[
[
918,
24,
843
]
],
[
[
918,
62,
479
],
[
479,
40,
843
]
],
[
[
918,
6,
12523
],
[
12523,
45,
843
]
],
[
[
918,
7,
4495
],
[
4495,
... | [
[
[
"Bicalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetrabenazine"
]
],
[
[
"Bicalutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Donepezil"
],
... | Bicalutamide may cause a minor interaction that can limit clinical effects when taken with Donepezil and Donepezil (Compound) resembles Tetrabenazine (Compound)
Bicalutamide (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Tetrabenazine (Compound)
Bicalutamide (Compound) upregulates CBR1 (Gene) and CBR1 (Ge... |
DB06589 | DB11575 | 1,250 | 1,676 | [
"DDInter1400",
"DDInter841"
] | Pazopanib | Grazoprevir | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Grazoprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common i... | Major | 2 | [
[
[
1250,
25,
1676
]
],
[
[
1250,
63,
723
],
[
723,
24,
1676
]
],
[
[
1250,
25,
868
],
[
868,
24,
1676
]
],
[
[
1250,
24,
1478
],
[
1478,
... | [
[
[
"Pazopanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Grazoprevir"
]
],
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
"Aprepitant"... | Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Grazoprevir
Pazopanib may lead to a major life threatening interaction when taken with Vemurafenib and Vemurafenib may cause... |
DB00220 | DB11828 | 798 | 1,406 | [
"DDInter1276",
"DDInter1281"
] | Nelfinavir | Neratinib | Nelfinavir is a potent HIV-1 protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles. | Neratinib was approved in July 2017 for use as an extended adjuvant therapy in Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer. Approval was granted to Puma Biotechnology Inc. for the tradename Nerlynx. Neratinib is currently under investigation for use in many other forms of cancer. | Major | 2 | [
[
[
798,
25,
1406
]
],
[
[
798,
25,
1135
],
[
1135,
23,
1406
]
],
[
[
798,
25,
392
],
[
392,
24,
1406
]
],
[
[
798,
24,
1195
],
[
1195,
... | [
[
[
"Nelfinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Neratinib"
]
],
[
[
"Nelfinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may ... | Nelfinavir may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Neratinib
Nelfinavir may lead to a major life threatening interaction when taken with Lapatinib and Lapatinib may cause a moderate interaction... |
DB00286 | DB09038 | 380 | 1,450 | [
"DDInter439",
"DDInter636"
] | Conjugated estrogens | Empagliflozin | The conjugated estrogens are noncrystalline mixtures of purified female sex hormones obtained either by its isolation from the urine of pregnant mares or by synthetic generation from vegetal material. Both of these products are later conjugated to natrium sulfate by ester bonds in order to make them more water soluble.... | Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 dia... | Moderate | 1 | [
[
[
380,
24,
1450
]
],
[
[
380,
24,
1486
],
[
1486,
24,
1450
]
],
[
[
380,
63,
1179
],
[
1179,
24,
1450
]
],
[
[
380,
24,
1017
],
[
1017,
... | [
[
[
"Conjugated estrogens",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Conjugated estrogens",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meth... | Conjugated estrogens may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Conjugated estrogens may cause a moderate interaction that could exacerbate disease... |
DB00196 | DB13074 | 600 | 877 | [
"DDInter743",
"DDInter1110"
] | Fluconazole | Macimorelin | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | Macimorelin, a novel and orally active ghrelin mimetic that stimulates GH secretion, is used in the diagnosis of adult GH deficiency (AGHD). More specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dep... | Major | 2 | [
[
[
600,
25,
877
]
],
[
[
600,
23,
112
],
[
112,
23,
877
]
],
[
[
600,
25,
651
],
[
651,
24,
877
]
],
[
[
600,
24,
673
],
[
673,
24,... | [
[
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
]
],
[
[
"Fluconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metron... | Fluconazole may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Macimorelin
Fluconazole may lead to a major life threatening interaction when taken with Fosphenytoin and Fosphenytoin m... |
DB05316 | DB09046 | 749 | 1,094 | [
"DDInter1467",
"DDInter1201"
] | Pimavanserin | Metreleptin | Pimavanserin is an atypical antipsychotic indicated for the treatment of psychiatric disorders. Although the exact mechanism of action is unknown, it is thought that pimavanserin interacts with the serotonin receptors, particularly the 5-HT<sub>2A</sub> and HT<sub>2C</sub> receptors. Unlike other atypical antipsychotic... | Metreleptin, a recombinant analog of the human hormone leptin, is an orphan drug used to treat complications of leptin deficiency in people with lipodystrophy. Lipodystrophies include a range of disorders characterized by the reduction, absence, or altered distribution of adipose tissue. Complications of lipodystrophy ... | Moderate | 1 | [
[
[
749,
24,
1094
]
],
[
[
749,
24,
578
],
[
578,
24,
1094
]
],
[
[
749,
63,
1213
],
[
1213,
24,
1094
]
],
[
[
749,
25,
39
],
[
39,
... | [
[
[
"Pimavanserin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metreleptin"
]
],
[
[
"Pimavanserin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
],
... | Pimavanserin may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Metreleptin
Pimavanserin may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Da... |
DB00008 | DB06210 | 491 | 72 | [
"DDInter1407",
"DDInter631"
] | Peginterferon alfa-2a | Eltrombopag | Peginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most co... | Eltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked well enough. ITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelet... | Major | 2 | [
[
[
491,
25,
72
]
],
[
[
491,
24,
384
],
[
384,
63,
72
]
],
[
[
491,
24,
467
],
[
467,
24,
72
]
],
[
[
491,
25,
1064
],
[
1064,
24,
... | [
[
[
"Peginterferon alfa-2a",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eltrombopag"
]
],
[
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
... | Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Eltrombopag
Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB00559 | DB00570 | 152 | 147 | [
"DDInter223",
"DDInter1936"
] | Bosentan | Vinblastine | Bosentan is a dual endothelin receptor antagonist marketed under the trade name Tracleer by Actelion Pharmaceuticals. Bosentan is used to treat pulmonary hypertension by blocking the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure. | Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.) | Moderate | 1 | [
[
[
152,
24,
147
]
],
[
[
152,
63,
134
],
[
134,
24,
147
]
],
[
[
152,
6,
8374
],
[
8374,
45,
147
]
],
[
[
152,
21,
29196
],
[
29196,
... | [
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinblastine"
]
],
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinorelbine"
],
[
... | Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine
Bosentan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vinblastine (Compound)
Bosentan (Compound... |
DB01115 | DB06772 | 336 | 310 | [
"DDInter1291",
"DDInter259"
] | Nifedipine | Cabazitaxel | Nifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar to [nicardipine].[A190210,A190273,A175390,L11383] Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972.[A175390,A190276] Since nifedipine's development,... | Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death. Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more ... | Moderate | 1 | [
[
[
336,
24,
310
]
],
[
[
336,
24,
973
],
[
973,
24,
310
]
],
[
[
336,
6,
7524
],
[
7524,
45,
310
]
],
[
[
336,
21,
28894
],
[
28894,
... | [
[
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
]
],
[
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
],
[
... | Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Nifedipine (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Cabazitaxel (Compound)
Nifedipine (Comp... |
DB00004 | DB11627 | 669 | 1,367 | [
"DDInter499",
"DDInter860"
] | Denileukin diftitox | Hepatitis B Vaccine (Recombinant) | A recombinant DNA-derived cytotoxic protein composed of the amino acid sequences for diphtheria toxin fragments A and B (Met 1-Thr 387)-His followed by the sequences for interleukin-2 (IL-2; Ala 1-Thr 133). It is produced in an E. coli expression system. | Hepatitis B Vaccine is an ingredient in the EMA-withdrawn product Quintanrix. It is marketed in Canada as Engerix B. It is also a part of Twinrix (Hep A/Hep B vaccine) available also in Canada. The hepatitis B virus induces a severe form of viral hepatitis. Other causative agents are hepatitis A virus, and the non-A, n... | Moderate | 1 | [
[
[
669,
24,
1367
]
],
[
[
669,
25,
1064
],
[
1064,
24,
1367
]
],
[
[
669,
24,
259
],
[
259,
24,
1367
]
],
[
[
669,
24,
738
],
[
738,
... | [
[
[
"Denileukin diftitox",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
]
],
[
[
"Denileukin diftitox",
"{u} may lead to a major life threatening interaction when taken with {v}",
"C... | Denileukin diftitox may lead to a major life threatening interaction when taken with Cladribine and Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Denileukin diftitox may cause a moderate interaction that could exacerbate diseases when taken ... |
DB06699 | DB11730 | 774 | 351 | [
"DDInter493",
"DDInter1588"
] | Degarelix | Ribociclib | Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. This antagonism reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH... | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Major | 2 | [
[
[
774,
25,
351
]
],
[
[
774,
62,
1247
],
[
1247,
23,
351
]
],
[
[
774,
63,
479
],
[
479,
23,
351
]
],
[
[
774,
63,
355
],
[
355,
2... | [
[
[
"Degarelix",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
]
],
[
[
"Degarelix",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfamet... | Degarelix may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Degarelix may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and D... |
DB09268 | DB12615 | 1,662 | 1,381 | [
"DDInter1464",
"DDInter1482"
] | Picosulfuric acid | Plazomicin | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been ... | Developed by Achaogen biopharmaceuticals, plazomicin is a next-generation aminoglycoside synthetically derived from . The structure of plazomicin was established via appending hydroxylaminobutyric acid to at position 1 and 2-hydroxyethyl group at position 6' . It was designed to evade all clinically relevant aminoglyco... | Moderate | 1 | [
[
[
1662,
24,
1381
]
],
[
[
1662,
63,
608
],
[
608,
23,
1381
]
],
[
[
1662,
63,
1479
],
[
1479,
24,
1381
]
],
[
[
1662,
63,
1441
],
[
1441... | [
[
[
"Picosulfuric acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Plazomicin"
]
],
[
[
"Picosulfuric acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
... | Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Plazomicin
Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalic... |
DB01268 | DB08871 | 1,151 | 36 | [
"DDInter1731",
"DDInter666"
] | Sunitinib | Eribulin | Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally av... | Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for... | Moderate | 1 | [
[
[
1151,
24,
36
]
],
[
[
1151,
63,
122
],
[
122,
23,
36
]
],
[
[
1151,
62,
1247
],
[
1247,
23,
36
]
],
[
[
1151,
63,
519
],
[
519,
... | [
[
[
"Sunitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eribulin"
]
],
[
[
"Sunitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Verapamil"
],
[
"... | Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Verapamil and Verapamil may cause a minor interaction that can limit clinical effects when taken with Eribulin
Sunitinib may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfametho... |
DB00981 | DB01173 | 1,528 | 358 | [
"DDInter1463",
"DDInter1349"
] | Physostigmine (ophthalmic) | Orphenadrine | Physostigmine is a carbamate ester and an indole alkaloid. It has a role as a miotic, an EC 3.1.1.8 (cholinesterase) inhibitor and an antidote to curare poisoning. | A muscarinic antagonist used to treat drug-induced parkinsonism and to relieve pain from muscle spasm. | Moderate | 1 | [
[
[
1528,
24,
358
]
],
[
[
1528,
24,
211
],
[
211,
1,
358
]
],
[
[
1528,
24,
272
],
[
272,
24,
358
]
],
[
[
1528,
24,
820
],
[
820,
... | [
[
[
"Physostigmine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orphenadrine"
]
],
[
[
"Physostigmine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolterodine"
],... | Physostigmine may cause a moderate interaction that could exacerbate diseases when taken with Orphenadrine
Physostigmine may cause a moderate interaction that could exacerbate diseases when taken with Tolterodine and Tolterodine (Compound) resembles Orphenadrine (Compound)
Physostigmine may cause a moderate interaction... |
DB00282 | DB09133 | 641 | 1,527 | [
"DDInter1383",
"DDInter965"
] | Pamidronic acid | Iothalamic acid | Pamidronic acid is a second generation, nitrogen containing bisphosphonate similar to [neridronic acid] and [alendronic acid]. Pamidronic acid was first described in the literature in 1977. The second generation bisphosphonates are less common as third generation bisphosphonates, such as [ibandronic acid], [zoledronic ... | Iothalamic acid is an iodine containing organic anion used as a diagnostic contrast agent. | Major | 2 | [
[
[
641,
25,
1527
]
],
[
[
641,
24,
589
],
[
589,
25,
1527
]
],
[
[
641,
1,
1199
],
[
1199,
25,
1527
]
],
[
[
641,
25,
629
],
[
629,
... | [
[
[
"Pamidronic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iothalamic acid"
]
],
[
[
"Pamidronic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cisplatin"
],
[
... | Pamidronic acid may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin and Cisplatin may lead to a major life threatening interaction when taken with Iothalamic acid
Pamidronic acid (Compound) resembles Ibandronate (Compound) and Ibandronate may lead to a major life threatening intera... |
DB00700 | DB11901 | 312 | 913 | [
"DDInter656",
"DDInter107"
] | Eplerenone | Apalutamide | Eplerenone, an aldosterone receptor antagonist similar to spironolactone, has been shown to produce sustained increases in plasma renin and serum aldosterone, consistent with inhibition of the negative regulatory feedback of aldosterone on renin secretion. The resulting increased plasma renin activity and aldosterone c... | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Res... | Minor | 0 | [
[
[
312,
23,
913
]
],
[
[
312,
64,
600
],
[
600,
24,
913
]
],
[
[
312,
1,
303
],
[
303,
24,
913
]
],
[
[
312,
25,
609
],
[
609,
24,
... | [
[
[
"Eplerenone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Apalutamide"
]
],
[
[
"Eplerenone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fluconazole"
],
[
"Fluconazol... | Eplerenone may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Eplerenone (Compound) resembles Medroxyprogesterone acetate (Compound) and Medroxyprogesterone acetate may cause a moderate ... |
DB01143 | DB06207 | 923 | 910 | [
"DDInter65",
"DDInter1667"
] | Amifostine | Silodosin | A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia. | Silodosin is a selective antagonist of alpha(α)-1 adrenergic receptors that binds to the α<sub>1A</sub> subtype with the highest affinity. α1-adrenergic receptors regulate smooth muscle tone in the bladder neck, prostate, and prostatic urethra: the α<sub>1A</sub> subtype accounts for approximately 75% of α1-adrenocepto... | Moderate | 1 | [
[
[
923,
24,
910
]
],
[
[
923,
21,
28921
],
[
28921,
60,
910
]
],
[
[
923,
63,
274
],
[
274,
24,
910
]
],
[
[
923,
21,
28921
],
[
28921,
... | [
[
[
"Amifostine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Silodosin"
]
],
[
[
"Amifostine",
"{u} (Compound) causes {v} (Side Effect)",
"Dizziness"
],
[
"Dizziness",
"{u} (Side Effect) is cause... | Amifostine (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Silodosin (Compound)
Amifostine may cause a moderate interaction that could exacerbate diseases when taken with Phentolamine and Phentolamine may cause a moderate interaction that could exacerbate diseases when taken with Silo... |
DB00153 | DB01320 | 1,331 | 651 | [
"DDInter662",
"DDInter783"
] | Ergocalciferol | Fosphenytoin | Ergocalciferol is an inactivated vitamin D analog. It is synthesized by some plants in the presence of UVB light. The production of ergocalciferol was prompted by the identification of dietary deficiency, more specifically vitamin D, as the main causative factor for the development of rickets. Ergocalciferol was isolat... | Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repe... | Moderate | 1 | [
[
[
1331,
24,
651
]
],
[
[
1331,
24,
362
],
[
362,
1,
651
]
],
[
[
1331,
6,
8374
],
[
8374,
45,
651
]
],
[
[
1331,
21,
28856
],
[
28856,
... | [
[
[
"Ergocalciferol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosphenytoin"
]
],
[
[
"Ergocalciferol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenytoin"
],... | Ergocalciferol may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Fosphenytoin (Compound)
Ergocalciferol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Fosphenytoin (Compound)
Ergocalciferol (Compound) causes Acidosis (Side Effect) ... |
DB01261 | DB01357 | 170 | 890 | [
"DDInter1679",
"DDInter1160"
] | Sitagliptin | Mestranol | Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus[FDA label,A2260,A2255,A2256]. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improv... | The 3-methyl ether of ethinyl estradiol. It must be demethylated to be biologically active. It is used as the estrogen component of many combination ORAL contraceptives. | Moderate | 1 | [
[
[
170,
24,
890
]
],
[
[
170,
63,
1197
],
[
1197,
40,
890
]
],
[
[
170,
24,
35
],
[
35,
40,
890
]
],
[
[
170,
63,
559
],
[
559,
1,
... | [
[
[
"Sitagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mestranol"
]
],
[
[
"Sitagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Norethisterone"
],
... | Sitagliptin may cause a moderate interaction that could exacerbate diseases when taken with Norethisterone and Norethisterone (Compound) resembles Mestranol (Compound)
Sitagliptin may cause a moderate interaction that could exacerbate diseases when taken with Quinestrol and Quinestrol (Compound) resembles Mestranol (Co... |
DB01254 | DB12301 | 1,213 | 907 | [
"DDInter484",
"DDInter585"
] | Dasatinib | Doravirine | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Doravirine is an HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) intended to be administered in combination with other antiretroviral medicines.[L12729,L4562] Doravirine is available by itself or as a combination product of doravirine (100 mg), lamivudine (300 mg), and tenofovir disoproxil fumarate (300 mg... | Minor | 0 | [
[
[
1213,
23,
907
]
],
[
[
1213,
24,
1478
],
[
1478,
23,
907
]
],
[
[
1213,
24,
159
],
[
159,
62,
907
]
],
[
[
1213,
63,
600
],
[
600,
... | [
[
[
"Dasatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Doravirine"
]
],
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
],
[
"... | Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may cause a minor interaction that can limit clinical effects when taken with Doravirine
Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrect... |
DB00476 | DB01362 | 109 | 497 | [
"DDInter608",
"DDInter960"
] | Duloxetine | Iohexol | Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor.[label] It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. Duloxetine first received approval from the FDA in August, 2004 as Cymbalta for the treatment of Major Depressive Disorder. It has since received approval... | Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality. | Major | 2 | [
[
[
109,
25,
497
]
],
[
[
109,
21,
28681
],
[
28681,
60,
497
]
],
[
[
109,
24,
1574
],
[
1574,
63,
497
]
],
[
[
109,
63,
999
],
[
999,
... | [
[
[
"Duloxetine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
]
],
[
[
"Duloxetine",
"{u} (Compound) causes {v} (Side Effect)",
"Hypersensitivity"
],
[
"Hypersensitivity",
"{u} (Side Effect) is caused b... | Duloxetine (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Iohexol (Compound)
Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Urea and Urea may cause a moderate interaction that could exacerbate diseases when taken with Iohexol
... |
DB01174 | DB06589 | 697 | 1,250 | [
"DDInter1442",
"DDInter1400"
] | Phenobarbital | Pazopanib | A barbituric acid derivative that acts as a nonselective central nervous system depressant. It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations. | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Moderate | 1 | [
[
[
697,
24,
1250
]
],
[
[
697,
6,
7950
],
[
7950,
45,
1250
]
],
[
[
697,
21,
28658
],
[
28658,
60,
1250
]
],
[
[
697,
63,
112
],
[
112,
... | [
[
[
"Phenobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
]
],
[
[
"Phenobarbital",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compou... | Phenobarbital (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Pazopanib (Compound)
Phenobarbital (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Pazopanib (Compound)
Phenobarbital may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole ... |
DB01320 | DB06168 | 651 | 1,531 | [
"DDInter783",
"DDInter281"
] | Fosphenytoin | Canakinumab | Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repe... | Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. B... | Moderate | 1 | [
[
[
651,
24,
1531
]
],
[
[
651,
25,
1362
],
[
1362,
63,
1531
]
],
[
[
651,
63,
970
],
[
970,
24,
1531
]
],
[
[
651,
64,
1213
],
[
1213,
... | [
[
[
"Fosphenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
]
],
[
[
"Fosphenytoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Olaparib"
],
[
"Olapari... | Fosphenytoin may lead to a major life threatening interaction when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab
Fosphenytoin may cause a moderate interaction that could exacerbate diseases when taken with Fluorouracil and Fluorouracil may c... |
DB01088 | DB04865 | 714 | 4 | [
"DDInter908",
"DDInter1335"
] | Iloprost | Omacetaxine mepesuccinate | Iloprost is a mimetic of prostacyclin (PGI2; epoprostenol). Iloprost consists of a mixture of the 4R and 4S diastereoisomers at a ratio of approximately 53:47. It is a potent vasodilator with reported anti-thrombotic properties. | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the pla... | Major | 2 | [
[
[
714,
25,
4
]
],
[
[
714,
63,
453
],
[
453,
24,
4
]
],
[
[
714,
24,
738
],
[
738,
63,
4
]
],
[
[
714,
25,
39
],
[
39,
63,
4... | [
[
[
"Iloprost",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Iloprost",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linezolid"
],
[
"... | Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Linezolid and Linezolid may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Niraparib an... |
DB00543 | DB09472 | 87 | 1,383 | [
"DDInter82",
"DDInter1693"
] | Amoxapine | Sodium sulfate | Amoxapine, the <i>N</i>-demethylated derivative of the antipsychotic agent loxapine, is a dibenzoxazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, am... | Sodium Sulfate Anhydrous is the anhydrous, sodium salt form of sulfuric acid. Sodium sulfate anhydrous disassociates in water to provide sodium ions and sulfate ions. Sodium ion is the principal cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte disturbances. Sodium sulfate... | Moderate | 1 | [
[
[
87,
24,
1383
]
],
[
[
87,
24,
609
],
[
609,
24,
1383
]
],
[
[
87,
25,
1311
],
[
1311,
24,
1383
]
],
[
[
87,
63,
521
],
[
521,
24... | [
[
[
"Amoxapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Amoxapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
... | Amoxapine may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Amoxapine may lead to a major life threatening interaction when taken with Metoclopramide and Metoclo... |
DB00264 | DB00501 | 88 | 752 | [
"DDInter1200",
"DDInter380"
] | Metoprolol | Cimetidine | Metoprolol is a selective beta-1 blocker commonly employed as the succinate and tartrate derivatives depending if the formulation is designed to be of immediate release or extended release.[A175159, L5530] The possibility of the generation of these formulations comes from the lower systemic bioavailability of the succi... | A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant ... | Moderate | 1 | [
[
[
88,
24,
752
]
],
[
[
88,
6,
4973
],
[
4973,
45,
752
]
],
[
[
88,
21,
29134
],
[
29134,
60,
752
]
],
[
[
88,
23,
542
],
[
542,
23... | [
[
[
"Metoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
]
],
[
[
"Metoprolol",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Metoprolol (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Cimetidine (Compound)
Metoprolol (Compound) causes Flatulence (Side Effect) and Flatulence (Side Effect) is caused by Cimetidine (Compound)
Metoprolol may cause a minor interaction that can limit clinical effects when taken with Levothyroxine and Lev... |
DB00438 | DB01042 | 149 | 1,307 | [
"DDInter330",
"DDInter1144"
] | Ceftazidime | Melphalan | Bacteria possess a cell wall comprising a glycopeptide polymer commonly known as peptidoglycan, which is synthesized and remodelled through the action of a family of enzymes known as "penicillin-binding proteins" (PBPs). β-lactam antibiotics, including cephalosporins, are PBP inhibitors that, through inhibition of esse... | Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard.[A261150, A261155] Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-con... | Moderate | 1 | [
[
[
149,
24,
1307
]
],
[
[
149,
21,
28766
],
[
28766,
60,
1307
]
],
[
[
149,
24,
1287
],
[
1287,
24,
1307
]
],
[
[
149,
63,
329
],
[
329,
... | [
[
[
"Ceftazidime",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Melphalan"
]
],
[
[
"Ceftazidime",
"{u} (Compound) causes {v} (Side Effect)",
"Hypotension"
],
[
"Hypotension",
"{u} (Side Effect) is... | Ceftazidime (Compound) causes Hypotension (Side Effect) and Hypotension (Side Effect) is caused by Melphalan (Compound)
Ceftazidime may cause a moderate interaction that could exacerbate diseases when taken with Amphotericin B and Amphotericin B may cause a moderate interaction that could exacerbate diseases when taken... |
DB00831 | DB01261 | 1,178 | 170 | [
"DDInter1866",
"DDInter1679"
] | Trifluoperazine | Sitagliptin | A phenothiazine with actions similar to chlorpromazine. It is used as an antipsychotic and an antiemetic. | Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus[FDA label,A2260,A2255,A2256]. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improv... | Moderate | 1 | [
[
[
1178,
24,
170
]
],
[
[
1178,
6,
4973
],
[
4973,
45,
170
]
],
[
[
1178,
18,
9226
],
[
9226,
57,
170
]
],
[
[
1178,
21,
28921
],
[
28921... | [
[
[
"Trifluoperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
]
],
[
[
"Trifluoperazine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Co... | Trifluoperazine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Sitagliptin (Compound)
Trifluoperazine (Compound) downregulates BPHL (Gene) and BPHL (Gene) is downregulated by Sitagliptin (Compound)
Trifluoperazine (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Sitagliptin... |
DB11828 | DB12130 | 1,406 | 1,017 | [
"DDInter1281",
"DDInter1094"
] | Neratinib | Lorlatinib | Neratinib was approved in July 2017 for use as an extended adjuvant therapy in Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer. Approval was granted to Puma Biotechnology Inc. for the tradename Nerlynx. Neratinib is currently under investigation for use in many other forms of cancer. | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Major | 2 | [
[
[
1406,
25,
1017
]
],
[
[
1406,
64,
1554
],
[
1554,
24,
1017
]
],
[
[
1406,
24,
1421
],
[
1421,
63,
1017
]
],
[
[
1406,
63,
14
],
[
14,
... | [
[
[
"Neratinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lorlatinib"
]
],
[
[
"Neratinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Colchicine"
],
[
"Colchicine",
"{u} may... | Neratinib may lead to a major life threatening interaction when taken with Colchicine and Colchicine may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Neratinib may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban and Betrixaban may cause a ... |
DB08912 | DB11979 | 1,040 | 1,320 | [
"DDInter462",
"DDInter625"
] | Dabrafenib | Elagolix | Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib... | Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the f... | Moderate | 1 | [
[
[
1040,
24,
1320
]
],
[
[
1040,
62,
168
],
[
168,
23,
1320
]
],
[
[
1040,
23,
1612
],
[
1612,
23,
1320
]
],
[
[
1040,
24,
1297
],
[
1297... | [
[
[
"Dabrafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Dabrafenib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bortezomib"
],
[
... | Dabrafenib may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Elagolix
Dabrafenib may cause a minor interaction that can limit clinical effects when taken with Fostemsavir and Fostemsavir m... |
DB01253 | DB08820 | 628 | 1,478 | [
"DDInter664",
"DDInter997"
] | Ergometrine | Ivacaftor | An ergot alkaloid with uterine and vascular smooth muscle contractile properties. | Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and... | Moderate | 1 | [
[
[
628,
24,
1478
]
],
[
[
628,
6,
8374
],
[
8374,
45,
1478
]
],
[
[
628,
21,
28762
],
[
28762,
60,
1478
]
],
[
[
628,
24,
985
],
[
985,
... | [
[
[
"Ergometrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
]
],
[
[
"Ergometrine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)"... | Ergometrine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ivacaftor (Compound)
Ergometrine (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Ivacaftor (Compound)
Ergometrine may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib and Osim... |
DB00346 | DB09330 | 472 | 985 | [
"DDInter44",
"DDInter1352"
] | Alfuzosin | Osimertinib | Benign prostatic hyperplasia (BPH) refers to a benign growth or hyperplasia of the prostate and leads to lower urinary tract symptoms in men, such as urgency, frequency and changes to urine flow. The prevalence of BPH is as high as 50%-60% for males in their 60's, and this prevalence increases to 80%-90% of those over ... | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Major | 2 | [
[
[
472,
25,
985
]
],
[
[
472,
23,
112
],
[
112,
23,
985
]
],
[
[
472,
24,
1478
],
[
1478,
24,
985
]
],
[
[
472,
24,
657
],
[
657,
6... | [
[
[
"Alfuzosin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
]
],
[
[
"Alfuzosin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidaz... | Alfuzosin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Alfuzosin may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaf... |
DB00467 | DB01177 | 1,467 | 77 | [
"DDInter644",
"DDInter904"
] | Enoxacin | Idarubicin | A broad-spectrum 6-fluoronaphthyridinone antibacterial agent (fluoroquinolones) structurally related to nalidixic acid. | An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. | Minor | 0 | [
[
[
1467,
23,
77
]
],
[
[
1467,
7,
11074
],
[
11074,
46,
77
]
],
[
[
1467,
7,
5178
],
[
5178,
57,
77
]
],
[
[
1467,
40,
739
],
[
739,
... | [
[
[
"Enoxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Idarubicin"
]
],
[
[
"Enoxacin",
"{u} (Compound) upregulates {v} (Gene)",
"HERC6"
],
[
"HERC6",
"{u} (Gene) is upregulated by {v} (Compoun... | Enoxacin (Compound) upregulates HERC6 (Gene) and HERC6 (Gene) is upregulated by Idarubicin (Compound)
Enoxacin (Compound) upregulates XBP1 (Gene) and XBP1 (Gene) is downregulated by Idarubicin (Compound)
Enoxacin (Compound) resembles Lomefloxacin (Compound) and Lomefloxacin may cause a minor interaction that can limit ... |
DB00024 | DB00491 | 818 | 127 | [
"DDInter1800",
"DDInter1217"
] | Thyrotropin alfa | Miglitol | Thyrotropin alfa is a recombinant form of thyroid stimulating hormone used in performing certain tests in patients who have or have had thyroid cancer. It is also used along with a radioactive agent to destroy remaining thyroid tissue in certain patients who have had their thyroid gland removed because of thyroid cance... | Miglitol inhibits the breakdown complex carbohydrates into glucose. It is primarily used in diabetes mellitus type 2 for establishing greater glycemic control by preventing the digestion of carbohydrates (such as disaccharides, oligosaccharides, and polysaccharides) into monosaccharides which can be absorbed by the bod... | Moderate | 1 | [
[
[
818,
24,
127
]
],
[
[
818,
24,
245
],
[
245,
24,
127
]
],
[
[
818,
24,
1021
],
[
1021,
63,
127
]
],
[
[
818,
24,
245
],
[
245,
5... | [
[
[
"Thyrotropin alfa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Miglitol"
]
],
[
[
"Thyrotropin alfa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
... | Thyrotropin alfa may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Miglitol
Thyrotropin alfa may cause a moderate interaction that could exacerbate diseases when taken with Pramlinti... |
DB00401 | DB09054 | 84 | 384 | [
"DDInter1298",
"DDInter905"
] | Nisoldipine | Idelalisib | Nisoldipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nisoldipine prevents calcium-dependent smooth muscle contractio... | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Moderate | 1 | [
[
[
84,
24,
384
]
],
[
[
84,
63,
58
],
[
58,
24,
384
]
],
[
[
84,
24,
891
],
[
891,
24,
384
]
],
[
[
84,
1,
409
],
[
409,
24,
... | [
[
[
"Nisoldipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Nisoldipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alefacept"
],
[
... | Nisoldipine may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Nisoldipine may cause a moderate interaction that could exacerbate diseases when taken with Prednisolone and Pred... |
DB11979 | DB13879 | 1,320 | 1,043 | [
"DDInter625",
"DDInter824"
] | Elagolix | Glecaprevir | Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the f... | Glecaprevir is a direct acting antiviral agent and Hepatitis C virus (HCV) NS3/4A protease inhibitor that targets the the viral RNA replication. In combination with , glecaprevir is a useful therapy for patients who experienced therapeutic failure from other NS3/4A protease inhibitors. It demonstrates a high genetic ba... | Moderate | 1 | [
[
[
1320,
24,
1043
]
],
[
[
1320,
63,
1135
],
[
1135,
23,
1043
]
],
[
[
1320,
63,
353
],
[
353,
24,
1043
]
],
[
[
1320,
24,
466
],
[
466,
... | [
[
[
"Elagolix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glecaprevir"
]
],
[
[
"Elagolix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
],
[
... | Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Glecaprevir
Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Griseofulvin and Griseofulvi... |
DB00030 | DB00741 | 1,685 | 167 | [
"DDInter934",
"DDInter885"
] | Insulin human | Hydrocortisone | Human Insulin, also known as Regular Insulin, is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Human insulin is produced by recombinant DNA technology and is identical to endogenously produced insulin. Typically prescribed for the management of diabetes mel... | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone wa... | Moderate | 1 | [
[
[
1685,
24,
167
]
],
[
[
1685,
24,
1220
],
[
1220,
40,
167
]
],
[
[
1685,
24,
870
],
[
870,
1,
167
]
],
[
[
1685,
24,
1561
],
[
1561,
... | [
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
... | Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) resembles Hydrocortisone (Compound)
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone (Compound) resemb... |
DB00782 | DB01122 | 1,123 | 158 | [
"DDInter1535",
"DDInter61"
] | Propantheline | Ambenonium | A muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment of ulcers. At high doses it has nicotinic effects resulting in neuromuscular blocking. | Ambenonium is a cholinesterase inhibitor. It is used in the management of myasthenia gravis. | Moderate | 1 | [
[
[
1123,
24,
158
]
],
[
[
1123,
63,
352
],
[
352,
24,
158
]
],
[
[
1123,
24,
1507
],
[
1507,
24,
158
]
],
[
[
1123,
24,
1511
],
[
1511,
... | [
[
[
"Propantheline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ambenonium"
]
],
[
[
"Propantheline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trospium"
],
... | Propantheline may cause a moderate interaction that could exacerbate diseases when taken with Trospium and Trospium may cause a moderate interaction that could exacerbate diseases when taken with Ambenonium
Propantheline may cause a moderate interaction that could exacerbate diseases when taken with Dicyclomine and Dic... |
DB08881 | DB13879 | 868 | 1,043 | [
"DDInter1925",
"DDInter824"
] | Vemurafenib | Glecaprevir | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Glecaprevir is a direct acting antiviral agent and Hepatitis C virus (HCV) NS3/4A protease inhibitor that targets the the viral RNA replication. In combination with , glecaprevir is a useful therapy for patients who experienced therapeutic failure from other NS3/4A protease inhibitors. It demonstrates a high genetic ba... | Moderate | 1 | [
[
[
868,
24,
1043
]
],
[
[
868,
23,
1135
],
[
1135,
23,
1043
]
],
[
[
868,
63,
353
],
[
353,
24,
1043
]
],
[
[
868,
24,
466
],
[
466,
... | [
[
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glecaprevir"
]
],
[
[
"Vemurafenib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
... | Vemurafenib may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Glecaprevir
Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Griseofulvin and Griseof... |
DB00158 | DB01299 | 356 | 698 | [
"DDInter771",
"DDInter1722"
] | Folic acid | Sulfadoxine | Folic acid, also known as folate or Vitamin B9, is a member of the B vitamin family and an essential cofactor for enzymes involved in DNA and RNA synthesis. More specifically, folic acid is required by the body for the synthesis of purines, pyrimidines, and methionine before incorporation into DNA or protein. Folic aci... | A long acting sulfonamide that is used, usually in combination with other drugs, for respiratory, urinary tract, and malarial infections. | Moderate | 1 | [
[
[
356,
24,
698
]
],
[
[
356,
24,
1247
],
[
1247,
40,
698
]
],
[
[
356,
24,
161
],
[
161,
1,
698
]
],
[
[
356,
35,
663
],
[
663,
24... | [
[
[
"Folic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfadoxine"
]
],
[
[
"Folic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfamethoxazole"
],
... | Folic acid may cause a moderate interaction that could exacerbate diseases when taken with Sulfamethoxazole and Sulfamethoxazole (Compound) resembles Sulfadoxine (Compound)
Folic acid may cause a moderate interaction that could exacerbate diseases when taken with Sulfadiazine and Sulfadiazine (Compound) resembles Sulfa... |
DB00624 | DB00912 | 1,561 | 473 | [
"DDInter1775",
"DDInter1581"
] | Testosterone | Repaglinide | Testosterone is a steroid sex hormone indicated to treat primary hypogonadism and hypogonadotropic hypogonadism.[L8983,L8935,L8938,L8986,L8989,L8992,L8995] Testosterone antagonizes the androgen receptor to induce gene expression that causes the growth and development of masculine sex organs and secondary sexual charact... | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response... | Moderate | 1 | [
[
[
1561,
24,
473
]
],
[
[
1561,
6,
1829
],
[
1829,
45,
473
]
],
[
[
1561,
21,
28763
],
[
28763,
60,
473
]
],
[
[
1561,
1,
1026
],
[
1026,... | [
[
[
"Testosterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
]
],
[
[
"Testosterone",
"{u} (Compound) binds {v} (Gene)",
"ALB"
],
[
"ALB",
"{u} (Gene) is bound by {v} (Compound)",
... | Testosterone (Compound) binds ALB (Gene) and ALB (Gene) is bound by Repaglinide (Compound)
Testosterone (Compound) causes Chest pain (Side Effect) and Chest pain (Side Effect) is caused by Repaglinide (Compound)
Testosterone (Compound) resembles Oxandrolone (Compound) and Oxandrolone may cause a moderate interaction th... |
DB05528 | DB08868 | 1,070 | 1,011 | [
"DDInter1228",
"DDInter737"
] | Mipomersen | Fingolimod | Mipomersen sodium, which was known as the investigational drug, isis-301012, is the salt form of a synthetic phosphorothioate oligonucleotide. Mipomersen sodium prevents the formation of apo B-100, resulting in a decrease in the levels of apolipoprotein B (apo B), low density lipoprotein (LDL), and total cholesterol. M... | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially appro... | Major | 2 | [
[
[
1070,
25,
1011
]
],
[
[
1070,
25,
1613
],
[
1613,
63,
1011
]
],
[
[
1070,
64,
267
],
[
267,
24,
1011
]
],
[
[
1070,
64,
1066
],
[
1066... | [
[
[
"Mipomersen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
],
[
[
"Mipomersen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Peginterferon beta-1a"
],
[
"Peginterferon ... | Mipomersen may lead to a major life threatening interaction when taken with Peginterferon beta-1a and Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod
Mipomersen may lead to a major life threatening interaction when taken with Naltrexone and Naltrexone may... |
DB00095 | DB06674 | 66 | 908 | [
"DDInter623",
"DDInter837"
] | Efalizumab | Golimumab | Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. The FDA approved efalizumab in 2003. It wa... | Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate t... | Moderate | 1 | [
[
[
66,
24,
908
]
],
[
[
66,
23,
1193
],
[
1193,
62,
908
]
],
[
[
66,
23,
1461
],
[
1461,
23,
908
]
],
[
[
66,
24,
496
],
[
496,
63,... | [
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Golimumab"
]
],
[
[
"Efalizumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
... | Efalizumab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Golimumab
Efalizumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitami... |
DB09100 | DB14491 | 320 | 428 | [
"DDInter1799",
"DDInter725"
] | Thyroid, porcine | Ferrous fumarate | Thyroid extract is dried and powdered thyroid glands from pigs containing tiiodothyronine (T3) and thyroxine (T4) used to supplement low or absent thyroid activity.[A190831,L11755] Thyroid extract has been described in literature to treat hypothyroidism since 1891 but its use dates back as far as the 6th century. Thyro... | Used in treatment of iron deficiency anemia. | Moderate | 1 | [
[
[
320,
24,
428
]
],
[
[
320,
63,
379
],
[
379,
24,
428
]
],
[
[
320,
24,
286
],
[
286,
24,
428
]
],
[
[
320,
63,
379
],
[
379,
63,... | [
[
[
"Thyroid, porcine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ferrous fumarate"
]
],
[
[
"Thyroid, porcine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rabeprazo... | Thyroid, porcine may cause a moderate interaction that could exacerbate diseases when taken with Rabeprazole and Rabeprazole may cause a moderate interaction that could exacerbate diseases when taken with Ferrous fumarate
Thyroid, porcine may cause a moderate interaction that could exacerbate diseases when taken with M... |
DB00067 | DB08881 | 317 | 868 | [
"DDInter1921",
"DDInter1925"
] | Vasopressin | Vemurafenib | Vasopressin (arginine-vasopressin or antidiuretic hormone) is a nonapeptide primarily produced in the hypothalamus that exhibits diverse physiological functions related to diuresis, hemodynamic modulation, and behaviour.[A110, A111, A112, A113, A228008] Vasopressin is very similar to oxytocin, differing in the third an... | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Major | 2 | [
[
[
317,
25,
868
]
],
[
[
317,
23,
112
],
[
112,
23,
868
]
],
[
[
317,
24,
480
],
[
480,
24,
868
]
],
[
[
317,
24,
144
],
[
144,
63,... | [
[
[
"Vasopressin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
]
],
[
[
"Vasopressin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metron... | Vasopressin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Vemurafenib
Vasopressin may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and F... |
DB00206 | DB06764 | 1,245 | 1,090 | [
"DDInter1582",
"DDInter1788"
] | Reserpine | Tetryzoline (ophthalmic) | An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria. Reserpine inhibits the uptake of norepinephrine into storage vesicles resulting in depletion of catecholamines and serotonin from central and peripheral axon terminals. It has been used as an antihypertensive and an antipsychotic as well as a rese... | Tetryzoline is a member of imidazolines and a carboxamidine. It has a role as a sympathomimetic agent and a nasal decongestant. It is a conjugate base of a tetryzoline(1+). | Moderate | 1 | [
[
[
1245,
24,
1090
]
],
[
[
1245,
24,
1148
],
[
1148,
24,
1090
]
],
[
[
1245,
40,
1340
],
[
1340,
24,
1090
]
],
[
[
1245,
37,
247
],
[
247... | [
[
[
"Reserpine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetryzoline"
]
],
[
[
"Reserpine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
],
[
... | Reserpine may cause a moderate interaction that could exacerbate diseases when taken with Tetryzoline
Reserpine may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Tetryzoline
Reserp... |
DB09272 | DB09488 | 412 | 103 | [
"DDInter632",
"DDInter23"
] | Eluxadoline | Acrivastine | Eluxadoline is a mixed mu-opioid receptor agonist, kappa-opioid receptor agonist, and a-delta opioid receptor antagonist indicated for use in diarrhea-predominant irritable bowel syndrome (IBS-D). The mu-, kappa-, and delta-opioid receptors mediate endogenous and exogenous opioid response in the central nervous system ... | Acrivastine is a triprolidine analog antihistamine indicated for the treatment of allergies and hay fever. As an H1 receptor antagonist, it functions by blocking the action of histamine at this receptor thereby preventing the symptoms associated with histamine release such as pruritis, vasodilation, hypotension, edema,... | Moderate | 1 | [
[
[
412,
24,
103
]
],
[
[
412,
63,
1405
],
[
1405,
24,
103
]
],
[
[
412,
24,
1536
],
[
1536,
63,
103
]
],
[
[
412,
63,
1405
],
[
1405,
... | [
[
[
"Eluxadoline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acrivastine"
]
],
[
[
"Eluxadoline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclobenzaprine"
],
... | Eluxadoline may cause a moderate interaction that could exacerbate diseases when taken with Cyclobenzaprine and Cyclobenzaprine may cause a moderate interaction that could exacerbate diseases when taken with Acrivastine
Eluxadoline may cause a moderate interaction that could exacerbate diseases when taken with Belladon... |
DB00030 | DB00635 | 1,685 | 1,573 | [
"DDInter934",
"DDInter1515"
] | Insulin human | Prednisone | Human Insulin, also known as Regular Insulin, is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Human insulin is produced by recombinant DNA technology and is identical to endogenously produced insulin. Typically prescribed for the management of diabetes mel... | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | Moderate | 1 | [
[
[
1685,
24,
1573
]
],
[
[
1685,
24,
175
],
[
175,
40,
1573
]
],
[
[
1685,
23,
1103
],
[
1103,
1,
1573
]
],
[
[
1685,
24,
251
],
[
251,
... | [
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisone"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
],... | Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Prednisone (Compound)
Insulin human may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide (Compound) resembles Prednisone (... |
DB00261 | DB00978 | 702 | 739 | [
"DDInter93",
"DDInter1084"
] | Anagrelide | Lomefloxacin | Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythe... | Lomefloxacin is a fluoroquinolone antibiotic, used to treat bacterial infections including bronchitis and urinary tract infections (UTIs). Additionally, it has been employed for the prophylaxis of UTIs prior to surgery as well. | Major | 2 | [
[
[
702,
25,
739
]
],
[
[
702,
25,
945
],
[
945,
40,
739
]
],
[
[
702,
64,
1176
],
[
1176,
1,
739
]
],
[
[
702,
24,
1467
],
[
1467,
... | [
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomefloxacin"
]
],
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sparfloxacin"
],
[
"Sparfloxacin",
... | Anagrelide may lead to a major life threatening interaction when taken with Sparfloxacin and Sparfloxacin (Compound) resembles Lomefloxacin (Compound)
Anagrelide may lead to a major life threatening interaction when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Lomefloxacin (Compound)
Anagrelide may cau... |
DB01234 | DB08938 | 1,220 | 1,384 | [
"DDInter513",
"DDInter1112"
] | Dexamethasone | Magaldrate | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Magaldrate is an antacid drug used for the treatment of esophagitis, duodenal and gastric ulcers, and gastroesophageal reflux. Magaldrate has been discontinued in the US market. | Minor | 0 | [
[
[
1220,
23,
1384
]
],
[
[
1220,
40,
167
],
[
167,
23,
1384
]
],
[
[
1220,
63,
699
],
[
699,
23,
1384
]
],
[
[
1220,
1,
891
],
[
891,
... | [
[
[
"Dexamethasone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magaldrate"
]
],
[
[
"Dexamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Hydrocortisone"
],
[
"Hydrocortisone",
"{u} may cau... | Dexamethasone (Compound) resembles Hydrocortisone (Compound) and Hydrocortisone may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Nadolol and Nadolol may cause a minor interaction that ca... |
DB00029 | DB01381 | 25 | 958 | [
"DDInter99",
"DDInter819"
] | Anistreplase | Ginkgo biloba | Human tissue plasminogen activator, purified, glycosylated, 527 residues purified from CHO cells. Eminase is a lyophilized (freeze-dried) formulation of anistreplase, the p-anisoyl derivative of the primary Lys-plasminogen-streptokinase activator complex (a complex of Lys-plasminogen and streptokinase). A p-anisoyl gro... | _Ginkgo biloba_ extract contains a group of terpene lactones (notably, ginkgolides and diterpenes) and ginkgo flavone glycosides (notably, ginkgetin, bilobetin, and sciadopitysin) that have antioxidant and vasoactive properties. Most of the studies that investigate the effect of _ginkgo biloba_ use the standardized ext... | Moderate | 1 | [
[
[
25,
24,
958
]
],
[
[
25,
24,
1347
],
[
1347,
24,
958
]
],
[
[
25,
25,
126
],
[
126,
24,
958
]
],
[
[
25,
25,
792
],
[
792,
63,
... | [
[
[
"Anistreplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginkgo biloba"
]
],
[
[
"Anistreplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clopidogrel"
],
... | Anistreplase may cause a moderate interaction that could exacerbate diseases when taken with Clopidogrel and Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Ginkgo biloba
Anistreplase may lead to a major life threatening interaction when taken with Warfarin and Warfarin may c... |
DB00261 | DB01105 | 702 | 222 | [
"DDInter93",
"DDInter1665"
] | Anagrelide | Sibutramine | Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythe... | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Moderate | 1 | [
[
[
702,
24,
222
]
],
[
[
702,
7,
2384
],
[
2384,
46,
222
]
],
[
[
702,
21,
29215
],
[
29215,
60,
222
]
],
[
[
702,
25,
839
],
[
839,
... | [
[
[
"Anagrelide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
]
],
[
[
"Anagrelide",
"{u} (Compound) upregulates {v} (Gene)",
"CDK6"
],
[
"CDK6",
"{u} (Gene) is upregulated by {v} (Co... | Anagrelide (Compound) upregulates CDK6 (Gene) and CDK6 (Gene) is upregulated by Sibutramine (Compound)
Anagrelide (Compound) causes Ecchymosis (Side Effect) and Ecchymosis (Side Effect) is caused by Sibutramine (Compound)
Anagrelide may lead to a major life threatening interaction when taken with Grepafloxacin and Grep... |
DB01129 | DB11901 | 379 | 913 | [
"DDInter1559",
"DDInter107"
] | Rabeprazole | Apalutamide | Rabeprazole is an antiulcer drug in the class of proton pump inhibitors. It is a prodrug - in the acid environment of the parietal cells it turns into active sulphenamide form. Rabeprazole inhibits the H+, K+ATPase of the coating gastric cells and dose-dependent oppresses basal and stimulated gastric acid secretion. | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Res... | Moderate | 1 | [
[
[
379,
24,
913
]
],
[
[
379,
63,
279
],
[
279,
24,
913
]
],
[
[
379,
25,
1250
],
[
1250,
24,
913
]
],
[
[
379,
24,
859
],
[
859,
2... | [
[
[
"Rabeprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Rabeprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anisindione"
],
... | Rabeprazole may cause a moderate interaction that could exacerbate diseases when taken with Anisindione and Anisindione may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Rabeprazole may lead to a major life threatening interaction when taken with Pazopanib and Pazopanib may cau... |
DB00047 | DB00722 | 176 | 743 | [
"DDInter932",
"DDInter1079"
] | Insulin glargine | Lisinopril | Insulin glargine is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas t... | Lisinopril is an angiotensin converting enzyme inhibitor (ACEI) used to treat hypertension, heart failure, and myocardial infarction.[L8384,L8387,L8390] Lisinopril and [captopril] are the only ACEIs that are not prodrugs. It functions by inhibition of angiotensin converting enzyme as well as the renin angiotensin aldos... | Moderate | 1 | [
[
[
176,
24,
743
]
],
[
[
176,
24,
610
],
[
610,
40,
743
]
],
[
[
176,
24,
1638
],
[
1638,
1,
743
]
],
[
[
176,
24,
5
],
[
5,
62,
... | [
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lisinopril"
]
],
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enalapril"
... | Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Enalapril and Enalapril (Compound) resembles Lisinopril (Compound)
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Trandolapril and Trandolapril (Compound) resembles Lisinopr... |
DB00206 | DB12364 | 1,245 | 1,421 | [
"DDInter1582",
"DDInter200"
] | Reserpine | Betrixaban | An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria. Reserpine inhibits the uptake of norepinephrine into storage vesicles resulting in depletion of catecholamines and serotonin from central and peripheral axon terminals. It has been used as an antihypertensive and an antipsychotic as well as a rese... | Betrixaban is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa . It was selected among all lead compounds due to its low hERG channel affinity while sustaining its factor Xa inhibition capacity . Betrixaban, now developed by Portola Pharmaceuticals ... | Moderate | 1 | [
[
[
1245,
24,
1421
]
],
[
[
1245,
24,
714
],
[
714,
25,
1421
]
],
[
[
1245,
24,
714
],
[
714,
23,
944
],
[
944,
62,
1421
]
],
[
[
1245,
... | [
[
[
"Reserpine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betrixaban"
]
],
[
[
"Reserpine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloprost"
],
[
... | Reserpine may cause a moderate interaction that could exacerbate diseases when taken with Iloprost and Iloprost may lead to a major life threatening interaction when taken with Betrixaban
Reserpine may cause a moderate interaction that could exacerbate diseases when taken with Iloprost and Iloprost may cause a minor in... |
DB00204 | DB09135 | 228 | 1,211 | [
"DDInter580",
"DDInter967"
] | Dofetilide | Ioxilan | Dofetilide is a class III antiarrhythmic agent that is approved by the Food and Drug Administration (FDA) for the maintenance of sinus rhythm in individuals prone to the formation of atrial fibrillation and flutter, and for the chemical cardioversion to sinus rhythm from atrial fibrillation and flutter. | Ioxilan is a tri-iodinated diagnostic contrast agent. Intravascular injection results in opacification of vessels in the path of flow of the contrast medium, permitting radiographic visualization of the internal structures of the human body until significant hemodilution occurs. | Moderate | 1 | [
[
[
228,
24,
1211
]
],
[
[
228,
25,
1287
],
[
1287,
25,
1211
]
],
[
[
228,
24,
1645
],
[
1645,
25,
1211
]
],
[
[
228,
25,
1287
],
[
1287,
... | [
[
[
"Dofetilide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ioxilan"
]
],
[
[
"Dofetilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amphotericin B"
],
[
"Amphoteri... | Dofetilide may lead to a major life threatening interaction when taken with Amphotericin B and Amphotericin B may lead to a major life threatening interaction when taken with Ioxilan
Dofetilide may cause a moderate interaction that could exacerbate diseases when taken with Metformin and Metformin may lead to a major li... |
DB00595 | DB14509 | 1,545 | 1,399 | [
"DDInter1374",
"DDInter1081"
] | Oxytetracycline | Lithium carbonate | A tetracycline analog isolated from the actinomycete streptomyces rimosus and used in a wide variety of clinical conditions. | Lithium has been used to treat manic episodes since the 19th century. Though it is widely used, its mechanism of action is still unknown[FDA Label][A14585,A176642,A176651,L5843]. Lithium carbonate has a narrow therapeutic range and so careful monitoring is required to avoid adverse effects[FDA Label]. | Minor | 0 | [
[
[
1545,
23,
1399
]
],
[
[
1545,
40,
964
],
[
964,
23,
1399
]
],
[
[
1545,
63,
1031
],
[
1031,
24,
1399
]
],
[
[
1545,
24,
1254
],
[
1254... | [
[
[
"Oxytetracycline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Oxytetracycline",
"{u} (Compound) resembles {v} (Compound)",
"Doxycycline"
],
[
"Doxycycline",
"{u} ma... | Oxytetracycline (Compound) resembles Doxycycline (Compound) and Doxycycline may cause a minor interaction that can limit clinical effects when taken with Lithium carbonate
Oxytetracycline may cause a moderate interaction that could exacerbate diseases when taken with Theophylline and Theophylline may cause a moderate i... |
DB01599 | DB05812 | 1,232 | 1,374 | [
"DDInter1523",
"DDInter8"
] | Probucol | Abiraterone | A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993). | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | Moderate | 1 | [
[
[
1232,
24,
1374
]
],
[
[
1232,
62,
112
],
[
112,
23,
1374
]
],
[
[
1232,
63,
1494
],
[
1494,
24,
1374
]
],
[
[
1232,
24,
594
],
[
594,
... | [
[
[
"Probucol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
]
],
[
[
"Probucol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Probucol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Abiraterone
Probucol may cause a moderate interaction that could exacerbate diseases when taken with Palonosetron and Palon... |
DB00762 | DB09034 | 613 | 1,313 | [
"DDInter973",
"DDInter1733"
] | Irinotecan | Suvorexant | Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cel... | Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia. | Moderate | 1 | [
[
[
613,
24,
1313
]
],
[
[
613,
24,
1213
],
[
1213,
24,
1313
]
],
[
[
613,
24,
1619
],
[
1619,
63,
1313
]
],
[
[
613,
63,
353
],
[
353,
... | [
[
[
"Irinotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Suvorexant"
]
],
[
[
"Irinotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
],
[
... | Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Suvorexant
Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib... |
DB01181 | DB04908 | 1,532 | 1,671 | [
"DDInter906",
"DDInter741"
] | Ifosfamide | Flibanserin | Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent. | Flibanserin is the first drug to be approved for hypoactive sexual desire disorder (HSDD) in premenopausal women by the FDA in August 2015. It was originally developed as an antidepressant medication by Boehringer Ingelheim, but showed lack of efficacy in trials and was further developed as a hypoactive sexual disorder... | Moderate | 1 | [
[
[
1532,
24,
1671
]
],
[
[
1532,
24,
98
],
[
98,
63,
1671
]
],
[
[
1532,
24,
830
],
[
830,
24,
1671
]
],
[
[
1532,
63,
1594
],
[
1594,
... | [
[
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flibanserin"
]
],
[
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
],
[
... | Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Flibanserin
Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Phenindamine and Phenind... |
DB00794 | DB11967 | 759 | 710 | [
"DDInter1521",
"DDInter210"
] | Primidone | Binimetinib | Primidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures. Primidone was developed by J Yule Bogue and H C Carrington in 1949. Primidone was granted FDA Approval on 8 March 1954. | Binimetinib, also known as _Mektovi_, is a potent and selective oral mitogen-activated protein kinase 1/2 (MEK 1/2) inhibitor which is combined with [Encorafenib].[A34275,L3335] On June 27, 2018, the Food and Drug Administration approved the combination of [Encorafenib] and binimetinib (BRAFTOVI and MEKTOVI, from Array... | Moderate | 1 | [
[
[
759,
24,
710
]
],
[
[
759,
25,
1593
],
[
1593,
24,
710
]
],
[
[
759,
63,
883
],
[
883,
24,
710
]
],
[
[
759,
24,
1619
],
[
1619,
... | [
[
[
"Primidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Binimetinib"
]
],
[
[
"Primidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
],
[
"Crizotinib"... | Primidone may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Primidone may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib and Gefitinib may cause a m... |
DB00477 | DB06788 | 216 | 1,616 | [
"DDInter363",
"DDInter864"
] | Chlorpromazine | Histrelin | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the tr... | Histrelin is a gonadotropin-releasing hormone (GnRH) agonist that acts as a potent inhibitor of gonadotropin when administered as an implant delivering continuous therapeutic doses. This drug is a synthetic analog of naturally occurring GnRH with a higher potency. Histrelin implants are non-biodegradable, diffusion-con... | Moderate | 1 | [
[
[
216,
24,
1616
]
],
[
[
216,
23,
112
],
[
112,
23,
1616
]
],
[
[
216,
24,
1342
],
[
1342,
24,
1616
]
],
[
[
216,
63,
1179
],
[
1179,
... | [
[
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Histrelin"
]
],
[
[
"Chlorpromazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Chlorpromazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Histrelin
Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin a... |
DB00986 | DB01278 | 1,192 | 1,021 | [
"DDInter834",
"DDInter1506"
] | Glycopyrronium | Pramlintide | Glycopyrronium, also known as NVA237 or glycopyrrolate, is a racemic mixture of two enantiomers. They are both quaternary ammonium compounds and long acting muscarinic antagonists. It is one of the most commonly prescribed anticholinergic medications.[A233535,A233540] Early research into glycopyrronium use was for its ... | Pramlintide is a relatively new adjunct treatment for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals. It is derived from amylin, a hormone that is released into the bloodstream, in a similar pattern as insulin, after a meal. Like insulin, amylin is deficient in individuals with diabetes. | Moderate | 1 | [
[
[
1192,
24,
1021
]
],
[
[
1192,
24,
1536
],
[
1536,
63,
1021
]
],
[
[
1192,
63,
1507
],
[
1507,
24,
1021
]
],
[
[
1192,
23,
504
],
[
504... | [
[
[
"Glycopyrronium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pramlintide"
]
],
[
[
"Glycopyrronium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Belladonna"
],... | Glycopyrronium may cause a moderate interaction that could exacerbate diseases when taken with Belladonna and Belladonna may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide
Glycopyrronium may cause a moderate interaction that could exacerbate diseases when taken with Dicyclomine ... |
DB00586 | DB00652 | 1,512 | 234 | [
"DDInter537",
"DDInter1421"
] | Diclofenac | Pentazocine | Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first... | The first mixed agonist-antagonist analgesic to be marketed. It is an agonist at the kappa and sigma opioid receptors and has a weak antagonist action at the mu receptor. (From AMA Drug Evaluations Annual, 1991, p97) | Moderate | 1 | [
[
[
1512,
24,
234
]
],
[
[
1512,
21,
29473
],
[
29473,
60,
234
]
],
[
[
1512,
24,
1259
],
[
1259,
63,
234
]
],
[
[
1512,
25,
256
],
[
256,... | [
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentazocine"
]
],
[
[
"Diclofenac",
"{u} (Compound) causes {v} (Side Effect)",
"Induration"
],
[
"Induration",
"{u} (Side Effect) is c... | Diclofenac (Compound) causes Induration (Side Effect) and Induration (Side Effect) is caused by Pentazocine (Compound)
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Baricitinib and Baricitinib may cause a moderate interaction that could exacerbate diseases when taken with Pe... |
DB01118 | DB09140 | 33 | 511 | [
"DDInter76",
"DDInter1367"
] | Amiodarone | Oxygen | Amiodarone is a benzofuran derivative, anti-arrhythmic drug used commonly in a variety of settings. Most known for its approved indication in life-threatening ventricular arrhythmias, it is also used off-label in the outpatient and inpatient setting for atrial fibrillation. Because of its ability to cause serious toxic... | Oxygen is an element displayed by the symbol O, and atomic number 8. It is an essential element for human survival. Decreased oxygen levels may be treated with medical oxygen therapy. Treatment with oxygen serves to increase blood oxygen levels and also exerts a secondary effect of decreasing blood flow resistance in t... | Major | 2 | [
[
[
33,
25,
511
]
],
[
[
33,
21,
28769
],
[
28769,
60,
329
],
[
329,
25,
511
]
],
[
[
33,
63,
58
],
[
58,
24,
329
],
[
329,
25,
51... | [
[
[
"Amiodarone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oxygen"
]
],
[
[
"Amiodarone",
"{u} (Compound) causes {v} (Side Effect)",
"Feeling abnormal"
],
[
"Feeling abnormal",
"{u} (Side Effect) is caused by... | Amiodarone (Compound) causes Feeling abnormal (Side Effect) and Feeling abnormal (Side Effect) is caused by Bleomycin (Compound) and Bleomycin may lead to a major life threatening interaction when taken with Oxygen
Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and ... |
DB08868 | DB15699 | 1,011 | 652 | [
"DDInter737",
"DDInter232"
] | Fingolimod | Brexucabtagene autoleucel | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially appro... | Mantle cell lymphoma is a heterogeneous sub-category of non-Hodgkin's lymphoma that can be classified as either an aggressive nodal or an indolent leukemic non-nodal variant. Despite the introduction of Bruton's tyrosine kinase (BTK) inhibitors such as [ibrutinib] and [acalabrutinib], the prognosis for MCL patients rem... | Major | 2 | [
[
[
1011,
25,
652
]
],
[
[
1011,
64,
259
],
[
259,
24,
652
]
],
[
[
1011,
63,
1430
],
[
1430,
24,
652
]
],
[
[
1011,
25,
270
],
[
270,
... | [
[
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brexucabtagene autoleucel"
]
],
[
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rilonacept"
],
[
"Rilonacept... | Fingolimod may lead to a major life threatening interaction when taken with Rilonacept and Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Brexucabtagene autoleucel
Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipu... |
DB01254 | DB11003 | 1,213 | 748 | [
"DDInter484",
"DDInter100"
] | Dasatinib | Anthrax vaccine | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Anthrax vaccine is a vaccine used for the pre- or post-exposure prophylaxis of disease in those at high risk of, suspected or confirmed exposure to *Bacillus anthracis*. It is subcutaneously or intramuscularly administered. It is derived from cell-free filtrates of microaerophilic cultures of an avirulent, nonencapsula... | Moderate | 1 | [
[
[
1213,
24,
748
]
],
[
[
1213,
63,
322
],
[
322,
24,
748
]
],
[
[
1213,
24,
594
],
[
594,
24,
748
]
],
[
[
1213,
24,
564
],
[
564,
... | [
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
],
[... | Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib and Bosu... |
DB01142 | DB01563 | 1,264 | 680 | [
"DDInter593",
"DDInter349"
] | Doxepin | Chloral hydrate | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | A hypnotic and sedative used in the treatment of insomnia. The safety margin is too narrow for chloral hydrate to be used as a general anesthetic in humans, but it is commonly used for that purpose in animal experiments. It is no longer considered useful as an anti-anxiety medication. | Moderate | 1 | [
[
[
1264,
24,
680
]
],
[
[
1264,
63,
272
],
[
272,
24,
680
]
],
[
[
1264,
25,
593
],
[
593,
24,
680
]
],
[
[
1264,
24,
1609
],
[
1609,
... | [
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloral hydrate"
]
],
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
],
... | Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Chloral hydrate
Doxepin may lead to a major life threatening interaction when taken with Bupropion and Bupropion m... |
DB00626 | DB00798 | 1,441 | 1,132 | [
"DDInter161",
"DDInter815"
] | Bacitracin | Gentamicin | Bacitracin is a combination of at least 9 bacitracins.[A955,A181952] 60-80% of commercially prepared bacitracin is bacitracin A. The bacillus that produces bacitracin was first isolated from a knee scrape in 1945 from the knee wound of a child named Margaret Tracy. Bacitracin was granted FDA approval on 29 July 1948.[A... | Gentamicin is a bactericidal aminoglycoside that was discovered and isolated from _Micromonospora purpurea_ in 1963. It is one of the most frequently prescribed aminoglycosides due to its spectrum of activity, low cost, and availability.[A234339,A234354] Gentamicin is effective against both gram-positive and gram-negat... | Major | 2 | [
[
[
1441,
25,
1132
]
],
[
[
1441,
7,
5415
],
[
5415,
57,
1132
]
],
[
[
1441,
21,
28787
],
[
28787,
60,
1132
]
],
[
[
1441,
25,
361
],
[
36... | [
[
[
"Bacitracin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gentamicin"
]
],
[
[
"Bacitracin",
"{u} (Compound) upregulates {v} (Gene)",
"UBQLN2"
],
[
"UBQLN2",
"{u} (Gene) is downregulated by {v} (Compound)",
... | Bacitracin (Compound) upregulates UBQLN2 (Gene) and UBQLN2 (Gene) is downregulated by Gentamicin (Compound)
Bacitracin (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Gentamicin (Compound)
Bacitracin may lead to a major life threatening interaction when taken with Neomycin and Neomy... |
DB01165 | DB12245 | 1,539 | 823 | [
"DDInter1325",
"DDInter1863"
] | Ofloxacin | Triclabendazole | A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication. | Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans.[FDA label, L5452] Fascioliasis is a parasitic infection often caused by the helminth, _Fasciola hepatica_, which is also known as “the common li... | Moderate | 1 | [
[
[
1539,
24,
823
]
],
[
[
1539,
62,
112
],
[
112,
23,
823
]
],
[
[
1539,
63,
1010
],
[
1010,
24,
823
]
],
[
[
1539,
24,
28
],
[
28,
... | [
[
[
"Ofloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
]
],
[
[
"Ofloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Ofloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Triclabendazole
Ofloxacin may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and M... |
DB11817 | DB14783 | 1,259 | 287 | [
"DDInter165",
"DDInter574"
] | Baricitinib | Diroximel fumarate | Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated... | Multiple Sclerosis (MS) is a chronic, debilitating neurological disease that can lead to profound cognitive and physical symptoms, severely affecting quality of life. It is the main cause of neurological disability not caused by trauma in the young adult population of both North America and Europe. Relapsing-remitting ... | Major | 2 | [
[
[
1259,
25,
287
]
],
[
[
1259,
64,
1101
],
[
1101,
24,
287
]
],
[
[
1259,
25,
1619
],
[
1619,
24,
287
]
],
[
[
1259,
63,
1430
],
[
1430,... | [
[
[
"Baricitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Baricitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
... | Baricitinib may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Baricitinib may lead to a major life threatening interaction when taken with Rucaparib and Rucaparib may cause a moder... |
DB00631 | DB08901 | 372 | 1,468 | [
"DDInter405",
"DDInter1492"
] | Clofarabine | Ponatinib | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaem... | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Moderate | 1 | [
[
[
372,
24,
1468
]
],
[
[
372,
24,
478
],
[
478,
24,
1468
]
],
[
[
372,
6,
17404
],
[
17404,
45,
1468
]
],
[
[
372,
7,
7669
],
[
7669,
... | [
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
]
],
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
... | Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Clofarabine (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Ponatinib (Compound)
Clofarabine (Compound)... |
DB01059 | DB09043 | 956 | 135 | [
"DDInter1313",
"DDInter36"
] | Norfloxacin | Albiglutide | A synthetic fluoroquinolone (fluoroquinolones) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA gyrase. | Albiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide was approved on A... | Moderate | 1 | [
[
[
956,
24,
135
]
],
[
[
956,
64,
126
],
[
126,
23,
135
]
],
[
[
956,
63,
1647
],
[
1647,
23,
135
]
],
[
[
956,
40,
739
],
[
739,
2... | [
[
[
"Norfloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Albiglutide"
]
],
[
[
"Norfloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Warfarin"
],
[
"Warfarin"... | Norfloxacin may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken with Albiglutide
Norfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Acarbose and Acarbose may cause a minor... |
DB00741 | DB01059 | 167 | 956 | [
"DDInter885",
"DDInter1313"
] | Hydrocortisone | Norfloxacin | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone wa... | A synthetic fluoroquinolone (fluoroquinolones) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA gyrase. | Major | 2 | [
[
[
167,
25,
956
]
],
[
[
167,
25,
872
],
[
872,
40,
956
]
],
[
[
167,
64,
1176
],
[
1176,
1,
956
]
],
[
[
167,
25,
1539
],
[
1539,
... | [
[
[
"Hydrocortisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Norfloxacin"
]
],
[
[
"Hydrocortisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gemifloxacin"
],
[
"Gemifloxacin",... | Hydrocortisone may lead to a major life threatening interaction when taken with Gemifloxacin and Gemifloxacin (Compound) resembles Norfloxacin (Compound)
Hydrocortisone may lead to a major life threatening interaction when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Norfloxacin (Compound)
Hydrocortiso... |
DB09068 | DB11901 | 1,427 | 913 | [
"DDInter1948",
"DDInter107"
] | Vortioxetine | Apalutamide | Vortioxetine is an antidepressant medication indicated for the treatment of major depressive disorder (MDD). It is classified as a serotonin modulator and stimulator (SMS) as it has a multimodal mechanism of action towards the serotonin neurotransmitter system whereby it simultaneously modulates one or more serotonin r... | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Res... | Moderate | 1 | [
[
[
1427,
24,
913
]
],
[
[
1427,
24,
1320
],
[
1320,
63,
913
]
],
[
[
1427,
64,
1133
],
[
1133,
24,
913
]
],
[
[
1427,
63,
1468
],
[
1468,... | [
[
[
"Vortioxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Vortioxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
],
[... | Vortioxetine may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Vortioxetine may lead to a major life threatening interaction when taken with Granisetron and Granisetron may cau... |
DB00501 | DB12141 | 752 | 971 | [
"DDInter380",
"DDInter817"
] | Cimetidine | Gilteritinib | A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant ... | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression... | Moderate | 1 | [
[
[
752,
24,
971
]
],
[
[
752,
23,
1135
],
[
1135,
23,
971
]
],
[
[
752,
23,
466
],
[
466,
62,
971
]
],
[
[
752,
24,
1097
],
[
1097,
... | [
[
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
... | Cimetidine may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Cimetidine may cause a minor interaction that can limit clinical effects when taken with Darolutamide and Darolutami... |
DB01390 | DB01592 | 1,117 | 1,596 | [
"DDInter1683",
"DDInter975"
] | Sodium bicarbonate | Iron | Sodium bicarbonate is a white, crystalline powder that is commonly used as a pH buffering agent, an electrolyte replenisher, systemic alkalizer and in topical cleansing solutions. | A metallic element found in certain minerals, in nearly all soils, and in mineral waters. It is an essential constituent of hemoglobin, cytochrome, and other components of respiratory enzyme systems. Its chief functions are in the transport of oxygen to tissue (hemoglobin) and in cellular oxidation mechanisms. Depletio... | Moderate | 1 | [
[
[
1117,
24,
1596
]
],
[
[
1117,
21,
29785
],
[
29785,
60,
1596
]
],
[
[
1117,
62,
752
],
[
752,
23,
1596
]
],
[
[
1117,
63,
1096
],
[
10... | [
[
[
"Sodium bicarbonate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iron"
]
],
[
[
"Sodium bicarbonate",
"{u} (Compound) causes {v} (Side Effect)",
"Abscess"
],
[
"Abscess",
"{u} (Side Effect) i... | Sodium bicarbonate (Compound) causes Abscess (Side Effect) and Abscess (Side Effect) is caused by Iron (Compound)
Sodium bicarbonate may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Iron
... |
DB00398 | DB01087 | 79 | 1,520 | [
"DDInter1702",
"DDInter1520"
] | Sorafenib | Primaquine | Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular ca... | An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Ad... | Moderate | 1 | [
[
[
79,
24,
1520
]
],
[
[
79,
25,
1487
],
[
1487,
64,
1520
]
],
[
[
79,
6,
12523
],
[
12523,
45,
1520
]
],
[
[
79,
21,
28722
],
[
28722,
... | [
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primaquine"
]
],
[
[
"Sorafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydroxychloroquine"
],
[
"Hydr... | Sorafenib may lead to a major life threatening interaction when taken with Hydroxychloroquine and Hydroxychloroquine may lead to a major life threatening interaction when taken with Primaquine
Sorafenib (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Primaquine (Compound)
Sorafenib (Compound) causes Nausea... |
DB08864 | DB11718 | 786 | 927 | [
"DDInter1595",
"DDInter640"
] | Rilpivirine | Encorafenib | Rilpivirine is non-nucleoside reverse transcriptase inhibitor (NNRTI) which is used for the treatment of HIV-1 infections in treatment-naive patients. It is a diarylpyrimidine derivative. The internal conformational flexibility of rilpivirine and the plasticity of it interacting binding site gives it a very high potenc... | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Moderate | 1 | [
[
[
786,
24,
927
]
],
[
[
786,
62,
112
],
[
112,
23,
927
]
],
[
[
786,
24,
720
],
[
720,
24,
927
]
],
[
[
786,
63,
372
],
[
372,
24,... | [
[
[
"Rilpivirine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Rilpivirine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Rilpivirine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Encorafenib
Rilpivirine may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil and ... |
DB06616 | DB10989 | 594 | 496 | [
"DDInter224",
"DDInter858"
] | Bosutinib | Hepatitis A Vaccine | Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q... | Hepatitis A viral infection can lead to significant morbidity and mortality, with signs and symptoms that include anorexia, nausea, vomiting, and liver failure. Known by several trade names, such as Havrix and Twinrix, the Hepatitis A vaccine has been formulated for immunization against hepatitis A virus (HAV) infectio... | Moderate | 1 | [
[
[
594,
24,
496
]
],
[
[
594,
63,
4
],
[
4,
24,
496
]
],
[
[
594,
24,
850
],
[
850,
24,
496
]
],
[
[
594,
24,
738
],
[
738,
63,
... | [
[
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
]
],
[
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesucc... | Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Bosutinib may cause a moderate interaction that could exacerbate diseases ... |
DB00046 | DB00214 | 1,179 | 1,028 | [
"DDInter940",
"DDInter1836"
] | Insulin lispro | Torasemide | Insulin lispro is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promote... | Torasemide is a high-ceiling loop diuretic. Structurally, it is a pyridine-sulfonylurea used as an antihypertensive agent. Torasemide was first approved for clinical use by the FDA in 1993. | Moderate | 1 | [
[
[
1179,
24,
1028
]
],
[
[
1179,
24,
1545
],
[
1545,
62,
1028
]
],
[
[
1179,
24,
1450
],
[
1450,
63,
1028
]
],
[
[
1179,
24,
1324
],
[
13... | [
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Torasemide"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxytetracycline"
... | Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Oxytetracycline and Oxytetracycline may cause a minor interaction that can limit clinical effects when taken with Torasemide
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Empag... |
DB00282 | DB00781 | 641 | 1,481 | [
"DDInter1383",
"DDInter1489"
] | Pamidronic acid | Polymyxin B | Pamidronic acid is a second generation, nitrogen containing bisphosphonate similar to [neridronic acid] and [alendronic acid]. Pamidronic acid was first described in the literature in 1977. The second generation bisphosphonates are less common as third generation bisphosphonates, such as [ibandronic acid], [zoledronic ... | Polymyxin B was discovered in the 1940s. They are basic polypeptides of about eight amino acids and have cationic detergent action on cell membranes. Polymyxin B is used for infections with gram-negative organisms, but may be neurotoxic and nephrotoxic[A176426,FDA Label]. All gram-positive bacteria, fungi, and the gram... | Moderate | 1 | [
[
[
641,
24,
1481
]
],
[
[
641,
24,
1441
],
[
1441,
40,
1481
]
],
[
[
641,
21,
28719
],
[
28719,
60,
1481
]
],
[
[
641,
24,
91
],
[
91,
... | [
[
[
"Pamidronic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Polymyxin B"
]
],
[
[
"Pamidronic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bacitracin"
... | Pamidronic acid may cause a moderate interaction that could exacerbate diseases when taken with Bacitracin and Bacitracin (Compound) resembles Polymyxin B (Compound)
Pamidronic acid (Compound) causes Pain (Side Effect) and Pain (Side Effect) is caused by Polymyxin B (Compound)
Pamidronic acid may cause a moderate inter... |
DB00001 | DB08901 | 1,578 | 1,468 | [
"DDInter1037",
"DDInter1492"
] | Lepirudin | Ponatinib | Lepirudin is a recombinant hirudin formed by 65 amino acids that acts as a highly specific and direct thrombin inhibitor.[L41539,L41569] Natural hirudin is an endogenous anticoagulant found in _Hirudo medicinalis_ leeches. Lepirudin is produced in yeast cells and is identical to natural hirudin except for the absence o... | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Major | 2 | [
[
[
1578,
25,
1468
]
],
[
[
1578,
24,
1230
],
[
1230,
24,
1468
]
],
[
[
1578,
25,
932
],
[
932,
24,
1468
]
],
[
[
1578,
24,
41
],
[
41,
... | [
[
[
"Lepirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ponatinib"
]
],
[
[
"Lepirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Citalopram"
],
[
"Citalopram",
... | Lepirudin may cause a moderate interaction that could exacerbate diseases when taken with Citalopram and Citalopram may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Lepirudin may lead to a major life threatening interaction when taken with Mifepristone and Mifepristone may cause... |
DB00489 | DB06788 | 17 | 1,616 | [
"DDInter1704",
"DDInter864"
] | Sotalol | Histrelin | Sotalol is a methanesulfonanilide developed in 1960. It was the first of the class III anti arrhythmic drugs. Sotalol was first approved as an oral tablet on 30 October 1992. A racemic mixture of sotalol is currently formulated as a tablet, oral solution, and intravenous injection indicated for life threatening ventric... | Histrelin is a gonadotropin-releasing hormone (GnRH) agonist that acts as a potent inhibitor of gonadotropin when administered as an implant delivering continuous therapeutic doses. This drug is a synthetic analog of naturally occurring GnRH with a higher potency. Histrelin implants are non-biodegradable, diffusion-con... | Major | 2 | [
[
[
17,
25,
1616
]
],
[
[
17,
23,
112
],
[
112,
23,
1616
]
],
[
[
17,
25,
1342
],
[
1342,
24,
1616
]
],
[
[
17,
63,
1179
],
[
1179,
... | [
[
[
"Sotalol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Histrelin"
]
],
[
[
"Sotalol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
... | Sotalol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Histrelin
Sotalol may lead to a major life threatening interaction when taken with Romidepsin and Romidepsin may cause a mod... |
DB00633 | DB01612 | 614 | 1,637 | [
"DDInter520",
"DDInter92"
] | Dexmedetomidine | Amyl Nitrite | An agonist of receptors, adrenergic alpha-2 that is used in veterinary medicine for its analgesic and sedative properties. It is the racemate of dexmedetomidine. | Amyl Nitrite is an antihypertensive medicine. Amyl nitrite is employed medically to treat heart diseases such as angina and to treat cyanide poisoning. Its use as a prescription medicine comes from its ability to lower blood pressure. As an inhalant, it also has psychoactive effect which has led to illegal drug use. | Moderate | 1 | [
[
[
614,
24,
1637
]
],
[
[
614,
63,
475
],
[
475,
24,
1637
]
],
[
[
614,
24,
401
],
[
401,
24,
1637
]
],
[
[
614,
24,
407
],
[
407,
... | [
[
[
"Dexmedetomidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amyl Nitrite"
]
],
[
[
"Dexmedetomidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
]... | Dexmedetomidine may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Amyl Nitrite
Dexmedetomidine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine ... |
DB00193 | DB11730 | 534 | 351 | [
"DDInter1841",
"DDInter1588"
] | Tramadol | Ribociclib | Tramadol is a centrally acting synthetic opioid analgesic and SNRI (serotonin/norepinephrine reuptake-inhibitor) that is structurally related to [codeine] and [morphine]. Due to its good tolerability profile and multimodal mechanism of action, tramadol is generally considered a lower-risk opioid option for the treatmen... | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Major | 2 | [
[
[
534,
25,
351
]
],
[
[
534,
23,
112
],
[
112,
23,
351
]
],
[
[
534,
25,
222
],
[
222,
23,
351
]
],
[
[
534,
24,
283
],
[
283,
62,... | [
[
[
"Tramadol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
]
],
[
[
"Tramadol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole... | Tramadol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Tramadol may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may cause ... |
DB00574 | DB15982 | 121 | 1,339 | [
"DDInter717",
"DDInter193"
] | Fenfluramine | Berotralstat | Dravet syndrome is a pediatric encephalopathy that typically manifests within the first year of life following exposure to elevated temperatures. It is characterized by recurrent pharmacoresistant seizures, which increase in frequency and severity with disease progression. Concomitantly with these seizures, patients ty... | Berotralstat is a selective inhibitor of plasma kallikrein used in the prophylaxis of attacks of hereditary angioedema (HAE). It works by blocking the enzymatic activity of plasma kallikrein in releasing bradykinin, the major biologic peptide that promotes swelling and pain associated with attacks of HAE. Berotralstat ... | Moderate | 1 | [
[
[
121,
24,
1339
]
],
[
[
121,
25,
222
],
[
222,
23,
1339
]
],
[
[
121,
24,
283
],
[
283,
23,
1339
]
],
[
[
121,
24,
761
],
[
761,
... | [
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Berotralstat"
]
],
[
[
"Fenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sibutramine"
],
[
"Sib... | Fenfluramine may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Berotralstat
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may ... |
DB01246 | DB04948 | 820 | 1,084 | [
"DDInter45",
"DDInter1083"
] | Alimemazine | Lofexidine | A phenothiazine derivative that is used as an antipruritic. | Lofexidine is a non-opioid centrally acting alpha2-adrenergic receptor agonist that was first approved for the treatment of opioid withdrawal in the United Kingdom in 1992. It was first studied for use as an antihypertensive in 1980, but its researched was stopped as it was found less effective for the treatment of hyp... | Moderate | 1 | [
[
[
820,
24,
1084
]
],
[
[
820,
63,
1617
],
[
1617,
1,
1084
]
],
[
[
820,
62,
112
],
[
112,
23,
1084
]
],
[
[
820,
24,
774
],
[
774,
... | [
[
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lofexidine"
]
],
[
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apraclonidine"
],
... | Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Apraclonidine and Apraclonidine (Compound) resembles Lofexidine (Compound)
Alimemazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction t... |
DB00333 | DB06589 | 576 | 1,250 | [
"DDInter1166",
"DDInter1400"
] | Methadone | Pazopanib | Methadone is a potent synthetic analgesic that works as a full µ-opioid receptor (MOR) agonist and N-methyl-d-aspartate (NMDA) receptor antagonist. As a full MOR agonist, methadone mimics the natural effects of the body's opioids, endorphins, and enkephalins through the release of neurotransmitters involved in pain tra... | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Major | 2 | [
[
[
576,
25,
1250
]
],
[
[
576,
6,
7950
],
[
7950,
45,
1250
]
],
[
[
576,
21,
29264
],
[
29264,
60,
1250
]
],
[
[
576,
40,
307
],
[
307,
... | [
[
[
"Methadone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pazopanib"
]
],
[
[
"Methadone",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Pazopanib"... | Methadone (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Pazopanib (Compound)
Methadone (Compound) causes Rhinorrhoea (Side Effect) and Rhinorrhoea (Side Effect) is caused by Pazopanib (Compound)
Methadone (Compound) resembles Modafinil (Compound) and Modafinil may cause a minor interaction that can limit... |
DB01070 | DB01320 | 1,098 | 651 | [
"DDInter558",
"DDInter783"
] | Dihydrotachysterol | Fosphenytoin | A vitamin D that can be regarded as a reduction product of vitamin D2. | Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repe... | Moderate | 1 | [
[
[
1098,
24,
651
]
],
[
[
1098,
63,
362
],
[
362,
1,
651
]
],
[
[
1098,
64,
1041
],
[
1041,
24,
651
]
],
[
[
1098,
75,
1331
],
[
1331,
... | [
[
[
"Dihydrotachysterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosphenytoin"
]
],
[
[
"Dihydrotachysterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenytoin... | Dihydrotachysterol may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Fosphenytoin (Compound)
Dihydrotachysterol may lead to a major life threatening interaction when taken with Paricalcitol and Paricalcitol may cause a moderate interaction that ... |
DB00106 | DB11110 | 618 | 603 | [
"DDInter4",
"DDInter1115"
] | Abarelix | Magnesium citrate | Synthetic decapeptide antagonist to gonadotropin releasing hormone (GnRH). It is marketed by Praecis Pharmaceuticals as Plenaxis. Praecis announced in June 2006 that it was voluntarily withdrawing the drug from the market. | Magnesium citrate is a low volume and osmotic cathartic agent. The cathartic action works primarily through the high osmolarity of the solution which draws large amounts of fluid into space where is used. Magnesium citrate is considered by the FDA as an approved inactive ingredient for approved drug products under the ... | Moderate | 1 | [
[
[
618,
24,
603
]
],
[
[
618,
25,
57
],
[
57,
24,
603
]
],
[
[
618,
24,
789
],
[
789,
24,
603
]
],
[
[
618,
24,
484
],
[
484,
63,
... | [
[
[
"Abarelix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Abarelix",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
],
[
"A... | Abarelix may lead to a major life threatening interaction when taken with Arsenic trioxide and Arsenic trioxide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Foscarnet and Foscarn... |
DB00446 | DB15044 | 597 | 631 | [
"DDInter351",
"DDInter1738"
] | Chloramphenicol | Tafasitamab | An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The E... | Tafasitamab is a humanized, CD19-directed cytolytic monoclonal antibody intended for the treatment of B-cell malignancies. It is produced using recombinant DNA technology in Chinese hamster ovary cells, and contains an IgG1/2 hybrid Fc-domain which has been modified with 2 amino acid substitutions to enhance its cytoto... | Moderate | 1 | [
[
[
597,
24,
631
]
],
[
[
597,
24,
4
],
[
4,
24,
631
]
],
[
[
597,
63,
599
],
[
599,
24,
631
]
],
[
[
597,
63,
1057
],
[
1057,
25,
... | [
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tafasitamab"
]
],
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepe... | Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Tafasitamab
Chloramphenicol may cause a moderate interaction that could exacerbate disea... |
DB00497 | DB08816 | 828 | 578 | [
"DDInter1366",
"DDInter1802"
] | Oxycodone | Ticagrelor | Oxycodone is a semisynthetic opioid analgesic derived from thebaine in Germany in 1917. It is currently indicated as an immediate release product for moderate to severe pain and as an extended release product for chronic moderate to severe pain requiring continuous opioid analgesics for an extended period.[Label] The f... | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagre... | Moderate | 1 | [
[
[
828,
24,
578
]
],
[
[
828,
6,
8374
],
[
8374,
45,
578
]
],
[
[
828,
21,
28646
],
[
28646,
60,
578
]
],
[
[
828,
25,
723
],
[
723,
... | [
[
[
"Oxycodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Oxycodone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Oxycodone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ticagrelor (Compound)
Oxycodone (Compound) causes Unspecified disorder of skin and subcutaneous tissue (Side Effect) and Unspecified disorder of skin and subcutaneous tissue (Side Effect) is caused by Ticagrelor (Compound)
Oxycodone may lead to a ma... |
DB00531 | DB00619 | 450 | 1,419 | [
"DDInter456",
"DDInter909"
] | Cyclophosphamide | Imatinib | Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause steril... | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Moderate | 1 | [
[
[
450,
24,
1419
]
],
[
[
450,
6,
4973
],
[
4973,
45,
1419
]
],
[
[
450,
18,
5818
],
[
5818,
57,
1419
]
],
[
[
450,
21,
29016
],
[
29016,... | [
[
[
"Cyclophosphamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
]
],
[
[
"Cyclophosphamide",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Com... | Cyclophosphamide (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Imatinib (Compound)
Cyclophosphamide (Compound) downregulates ATP6V0B (Gene) and ATP6V0B (Gene) is downregulated by Imatinib (Compound)
Cyclophosphamide (Compound) causes Menorrhagia (Side Effect) and Menorrhagia (Side Effect) is caused by Imat... |
DB00759 | DB06723 | 1,620 | 115 | [
"DDInter1783",
"DDInter58"
] | Tetracycline | Aluminum hydroxide | Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some e... | Aluminum hydroxide is an inorganic salt used as an antacid. It is a basic compound that acts by neutralizing hydrochloric acid in gastric secretions. Subsequent increases in pH may inhibit the action of pepsin. An increase in bicarbonate ions and prostaglandins may also confer cytoprotective effects. | Moderate | 1 | [
[
[
1620,
24,
115
]
],
[
[
1620,
24,
1482
],
[
1482,
23,
115
]
],
[
[
1620,
63,
1252
],
[
1252,
23,
115
]
],
[
[
1620,
24,
339
],
[
339,
... | [
[
[
"Tetracycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aluminum hydroxide"
]
],
[
[
"Tetracycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digitoxin"
... | Tetracycline may cause a moderate interaction that could exacerbate diseases when taken with Digitoxin and Digitoxin may cause a minor interaction that can limit clinical effects when taken with Aluminum hydroxide
Tetracycline may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and D... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.